Business
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP’) of the European Medicines Agency has adopted a positive opinion recommending the granting of the marketing authorisation for EURneffy® (the trade name for neffy® in the EU) to include a 1 mg nasal adrenaline spray for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopa
About this update from Alk-abello A/s Class B
[{"type":"image","alt":"ALK Abello","displaySize":"","headline":null,"caption":"ALK Abello","className":"","disableSlideshowImg":false,"size":{"original":{"width":142,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/a84b59e43cd2eb1b97add5c2b0dfe2b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gfL7lNIX7z950ZiB3KRYoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a84b59e43cd2eb1b97add5c2b0dfe2b1","width":142,"height":39}},"lazy":false},{"type":"text","content":"Inside Information","length":18,"tagName":"p"},{"type":"text","content":"ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP’) of the European Medicines Agency has adopted a positive opinion recommending the granting of the marketing authorisation for EURneffy® (the trade name for neffy® in the EU) to include a 1 mg nasal adrenaline spray for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis in children aged 4 years and older with a bodyweight between 15 kg and 30 kg.","length":600,"tagName":"p"},{"type":"text","content":"The positive CHMP opinion supports an extension to the existing marketing authorisation for EURneffy® 2 mg granted by the European Commission (‘EC’) in August 2024 for the emergency treatment of anaphylaxis in adults and children who weigh ≥30 kg.","length":247,"tagName":"p"},{"type":"text","content":"Executive Vice President of R&D, Henriette Mersebach (MD) said: “We are delighted with the European health authorities’ recommendation to grant the EURneffy® 1 mg marketing authorisation which, if approved, will reinforce our paediatric focus by complementing the tablet approvals already obtained for treatment of children with respiratory allergy. EURneffy® 1 mg has the potential to transform the lives of those living with or caring for children with severe allergic reactions, offering a needle-free, ready-to-use adrenaline solution.”","length":544,"tagName":"p"},{"type":"text","content":"The CHMP opinion will now be reviewed by the EC. If granted, the marketing authorisation, which is expected within the coming months, will be valid in all EU member states, as well as Iceland, Liechtenstein and Norway.","length"...